Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,633,264
  • Shares Outstanding, K 52,999
  • Annual Sales, $ 1,106 M
  • Annual Income, $ 54,500 K
  • 60-Month Beta 1.26
  • Price/Sales 4.26
  • Price/Cash Flow 20.57
  • Price/Book 4.49
Trade EBS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate 2.72
  • Number of Estimates 2
  • High Estimate 2.85
  • Low Estimate 2.59
  • Prior Year 1.57
  • Growth Rate Est. (year over year) +73.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.07 +22.07%
on 12/16/20
110.65 -3.94%
on 01/13/21
+17.00 (+19.04%)
since 12/15/20
3-Month
77.73 +36.74%
on 11/23/20
110.65 -3.94%
on 01/13/21
+6.74 (+6.77%)
since 10/15/20
52-Week
46.37 +129.22%
on 03/23/20
137.61 -22.76%
on 08/06/20
+51.33 (+93.40%)
since 01/15/20

Most Recent Stories

More News
SmarTrend Watching for Potential Pullback in Shares of Emergent Biosolu After 4.41% Gain

Emergent Biosolu (NYSE:EBS) traded in a range yesterday that spanned from a low of $104.00 to a high of $108.67. Yesterday, the shares gained 4.4%, which took the trading range above the 3-day high of...

EBS : 106.29 (+0.28%)
Emergent (EBS) Posts Preliminary '20 Results, Gives 2021 View

Emergent (EBS) tightens revenue view for 2020 and expects a consistent rise in sales of contract development and manufacturing services provided to other companies.

JNJ : 160.30 (-0.22%)
NVAX : 127.43 (-1.96%)
EBS : 106.29 (+0.28%)
VXRT : 7.18 (-2.18%)
Emergent BioSolutions Announces 2021 Financial Guidance, Provides Preliminary 2020 Results

Emergent BioSolutions Inc. (NYSE:EBS) today announced its financial forecast for 2021 and selected preliminary unaudited financial results for 2020.

EBS : 106.29 (+0.28%)
3 Reasons Why Growth Investors Shouldn't Overlook Emergent Biosolutions (EBS)

Emergent Biosolutions (EBS) is well positioned to outperform the market, as it exhibits above-average growth in financials.

EBS : 106.29 (+0.28%)
Emergent Biosolutions (EBS) Outpaces Stock Market Gains: What You Should Know

Emergent Biosolutions (EBS) closed the most recent trading day at $97.97, moving +1.01% from the previous trading session.

EBS : 106.29 (+0.28%)
Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?

Is (EBS) Outperforming Other Medical Stocks This Year?

EBS : 106.29 (+0.28%)
Emergent BioSolutions to Participate in Investor Conferences

Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's executive management team will participate in the following investor conferences in the first quarter of 2021:

JPM : 138.64 (-1.79%)
EBS : 106.29 (+0.28%)
Company News for Dec 31, 2020

Companies In The News Are: MKC, EBS, FOXA, AAPL

AAPL : 127.14 (-1.37%)
EBS : 106.29 (+0.28%)
MKC : 93.43 (+1.98%)
FOXA : 31.49 (+0.70%)
Emergent BioSolutions and Mount Sinai Health System Announce Initiation of DOD-Funded Clinical Program to Evaluate COVID-19 Human Hyperimmune Globulin (COVID-HIG) Product Candidate for Prophylaxis

Emergent BioSolutions (NYSE: EBS) and Mount Sinai Health System today announced initiation of the clinical program to evaluate Emergent's COVID-19 Human Hyperimmune Globulin (COVID-HIG) product candidate...

EBS : 106.29 (+0.28%)
Is Emergent BioSolutions (EBS) a Good Stock to Pick Now?

Is Emergent BioSolutions (EBS) a great pick from the value investor's perspective right now? Read on to know more.

EBS : 106.29 (+0.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Business Summary

Emergent BioSolutions Inc. is strongly committed to the highest standards of ethical conduct and corporate governance. These standards are consistent with their corporate culture. The company understands that adhering to sound principles of corporate governance is critical to earning and maintaining...

See More

Key Turning Points

3rd Resistance Point 111.39
2nd Resistance Point 109.66
1st Resistance Point 107.97
Last Price 106.29
1st Support Level 104.56
2nd Support Level 102.83
3rd Support Level 101.14

See More

52-Week High 137.61
Last Price 106.29
Fibonacci 61.8% 102.76
Fibonacci 50% 91.99
Fibonacci 38.2% 81.22
52-Week Low 46.37

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar